NovoCure Limited NVCR Equity Alert Robbins LLP Urges NVCR Investors with Significant Losses to Contact the Law Firm Regarding the NovoCure Limited Class Action

SAN DIEGO, June 30, 2023 (GLOBE NEWSWIRE) — Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired NovoCure Limited (NASDAQ: NVCR) securities between January 5, 2023 and June 5, 2023. NovoCure Limited is an oncology company…Read More

Leave a Reply

Your email address will not be published. Required fields are marked *